These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

928 related items for PubMed ID: 18021088

  • 21. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Rajkumar SV, Lacy MQ, Kyle RA.
    Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S, Ludek P, Zdeněk A, Marta K, Martin Š, Sabina Š, Zdeněk K.
    Klin Onkol; 2018 Sep; 31(4):270-276. PubMed ID: 30541309
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, Dean PG, Prieto M, Kyle RA, Rajkumar SV, Leung N.
    Am J Nephrol; 2012 Sep; 35(4):365-71. PubMed ID: 22473253
    [Abstract] [Full Text] [Related]

  • 26. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
    Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC.
    Oncology (Williston Park); 2011 Jun; 25(7):594, 596. PubMed ID: 21888257
    [No Abstract] [Full Text] [Related]

  • 27. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
    Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE.
    J Clin Oncol; 2005 Aug 20; 23(24):5668-74. PubMed ID: 16110026
    [Abstract] [Full Text] [Related]

  • 28. Clinical practice. Monoclonal gammopathy of undetermined significance.
    Bladé J.
    N Engl J Med; 2006 Dec 28; 355(26):2765-70. PubMed ID: 17192542
    [No Abstract] [Full Text] [Related]

  • 29. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O, Heider U, Zavrski I, Possinger K.
    Haematologica; 2001 Aug 28; 86(8):837-43. PubMed ID: 11522540
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.
    Int J Lab Hematol; 2016 May 28; 38 Suppl 1():110-22. PubMed ID: 27161311
    [Abstract] [Full Text] [Related]

  • 33. [Retrospective analysis of progression to multiple myeloma or related disorders in 114 patients with monoclonal gammopathy of undetermined significance in a single institute].
    Yokota S, Urasaki Y, Nakamura Y, Bessho M.
    Rinsho Ketsueki; 2012 Mar 28; 53(3):303-9. PubMed ID: 22499046
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A, Ortuño FJ, Osma Mdel M, Español I, González AD, Roldán V, de Arriba F, Vicente V.
    Ann Med; 2009 Mar 28; 41(7):547-58. PubMed ID: 19634064
    [Abstract] [Full Text] [Related]

  • 36. Clinical aspects of multiple myeloma and related disorders including amyloidosis.
    Kyle RA.
    Pathol Biol (Paris); 1999 Feb 28; 47(2):148-57. PubMed ID: 10192881
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
    Rossi F, Petrucci MT, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, Depaoli L, Baldini L.
    Clin Cancer Res; 2009 Jul 01; 15(13):4439-45. PubMed ID: 19509142
    [Abstract] [Full Text] [Related]

  • 40. IgG subclasses in monoclonal gammopathy of undetermined significance.
    Kyle RA, Gleich GJ.
    J Lab Clin Med; 1982 Nov 01; 100(5):806-14. PubMed ID: 7130836
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.